Aurinia Pharmaceuticals Inc (AUPH) was Reiterated by H.C. Wainwright to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 10 from a previous price target of $7 . H.C. Wainwright advised their investors in a research report released on Aug 17, 2016.
Many Wall Street Analysts have commented on Aurinia Pharmaceuticals Inc. H.C. Wainwright Initiated Aurinia Pharmaceuticals Inc on Jun 30, 2016 to “Buy”, Price Target of the shares are set at $7.
Aurinia Pharmaceuticals Inc closed down -2.28 points or -55.75% at $1.81 with 1,18,92,637 shares getting traded on Monday. Post opening the session at $2.18, the shares hit an intraday low of $1.7375 and an intraday high of $2.2 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate voclosporin which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug administered twice daily. It is structurally similar to cyclosporine A (CsA) but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease the requirement for life-long dialysis or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Company’s wholly owned subsidiaries include Aurinia Pharmaceuticals Inc. and Aurinia Pharma Limited.